MARC details
| 000 -LEADER |
|---|
| fixed length control field |
03491nam a22004097a 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
230721s20232023 xxu||||| |||| 00| 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
|---|
| International Standard Serial Number |
2328-8957 |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
10.1093/ofid/ofad225 [doi] |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
ofad225 [pii] |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
PMC10297016 [pmc] |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
Ovid MEDLINE(R) |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| PMID |
37383243 |
| 245 ## - TITLE STATEMENT |
|---|
| Title |
Participant- and Disease-Related Factors as Independent Predictors of Treatment Outcomes in the RESTORE-IMI 2 Clinical Trial: A Multivariable Regression Analysis. |
| 251 ## - Source |
|---|
| Source |
Open Forum Infectious Diseases. 10(6):ofad225, 2023 Jun. |
| 252 ## - Abbreviated Source |
|---|
| Abbreviated source |
Open forum infect. dis.. 10(6):ofad225, 2023 Jun. |
| 253 ## - Journal Name |
|---|
| Journal name |
Open forum infectious diseases |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Year |
2023 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Manufacturer |
FY2023 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Publication date |
2023 Jun |
| 265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] |
|---|
| Publication status |
epublish |
| 265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] |
|---|
| Medline status |
PubMed-not-MEDLINE |
| 266 ## - Date added to catalog |
|---|
| Date added to catalog |
2023-07-21 |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
Background: In the RESTORE-IMI 2 trial, imipenem/cilastatin/relebactam (IMI/REL) was noninferior to piperacillin/tazobactam in treating hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia. This post hoc analysis was conducted to determine independent predictors of efficacy outcomes in the RESTORE-IMI 2 trial, to assist in treatment decision making. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
Clinical Trials Registration: NCT02493764. Copyright © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
Conclusions: This analysis, which accounted for baseline pathogen susceptibility, validated well-recognized patient- and disease-related factors as independent predictors of clinical outcomes. These results lend further support to the noninferiority of IMI/REL to piperacillin/tazobactam and suggests that pathogen eradication may be more likely with IMI/REL. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
Methods: A stepwise multivariable regression analysis was conducted to identify variables that were independently associated with day 28 all-cause mortality (ACM), favorable clinical response at early follow-up (EFU), and favorable microbiologic response at end of treatment (EOT). The analysis accounted for the number of baseline infecting pathogens and in vitro susceptibility to randomized treatment. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
Results: Vasopressor use, renal impairment, bacteremia at baseline, and Acute Physiologic Assessment and Chronic Health Evaluation (APACHE) II scores >=15 were associated with a greater risk of day 28 ACM. A favorable clinical response at EFU was associated with normal renal function, an APACHE II score <15, no vasopressor use, and no bacteremia at baseline. At EOT, a favorable microbiologic response was associated with IMI/REL treatment, normal renal function, no vasopressor use, nonventilated pneumonia at baseline, intensive care unit admission at randomization, monomicrobial infections at baseline, and absence of Acinetobacter calcoaceticus-baumannii complex at baseline. These factors remained significant after accounting for polymicrobial infection and in vitro susceptibility to assigned treatment. |
| 546 ## - LANGUAGE NOTE |
|---|
| Language note |
English |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Indexing |
Automated |
| 651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
|---|
| Institution |
MedStar Washington Hospital Center |
| 656 ## - INDEX TERM--OCCUPATION |
|---|
| Department |
Medicine/Pulmonary-Critical Care |
| 657 ## - INDEX TERM--FUNCTION |
|---|
| Medline publication type |
Journal Article |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Shorr, Andrew F |
| Institution Code |
MWHC |
| 790 ## - Authors |
|---|
| All authors |
Chen LF, DeRyke CA, Du J, Jensen EH, Kollef MH, Losada MC, Martin-Loeches I, Paschke A, Shorr AF, Wong M |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| DOI |
<a href="https://dx.doi.org/10.1093/ofid/ofad225">https://dx.doi.org/10.1093/ofid/ofad225</a> |
| Public note |
https://dx.doi.org/10.1093/ofid/ofad225 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Koha item type |
Journal Article |
| Item type description |
Article |
